You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEletriptan
Accession NumberDB00216  (APRD00945)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia]
Structure
Thumb
Synonyms
Eletriptanum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Gd-eletriptantablet20 mgoralGenmed A Division Of Pfizer Canada Inc2012-10-11Not applicableCanada
Gd-eletriptantablet40 mgoralGenmed A Division Of Pfizer Canada Inc2012-10-11Not applicableCanada
PMS-eletriptantablet20 mgoralPharmascience Inc2014-11-26Not applicableCanada
PMS-eletriptantablet40 mgoralPharmascience Inc2014-11-26Not applicableCanada
Relpaxtablet40 mgoralPfizer Canada Inc2004-10-13Not applicableCanada
Relpaxtablet, film coated20 mg/1oralRoerig2002-12-26Not applicableUs
Relpaxtablet, film coated40 mg/1oralPhysicians Total Care, Inc.2007-11-19Not applicableUs
Relpaxtablet, film coated40 mg/1oralRoerig2002-12-26Not applicableUs
Relpaxtablet, film coated40 mg/1oralU.S. Pharmaceuticals2002-12-26Not applicableUs
Relpaxtablet, film coated40 mg/1oralSTAT Rx USA LLC2002-12-26Not applicableUs
Relpaxtablet20 mgoralPfizer Canada Inc2004-10-13Not applicableCanada
Relpaxtablet, film coated40 mg/1oralRebel Distributors Corp2002-12-26Not applicableUs
Teva-eletriptantablet40 mgoralTeva Canada Limited2013-12-20Not applicableCanada
Teva-eletriptantablet20 mgoralTeva Canada Limited2013-12-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-eletriptantablet20 mgoralApotex Inc2013-09-12Not applicableCanada
Apo-eletriptantablet40 mgoralApotex Inc2013-09-12Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Eletriptan hydrobromide
ThumbNot applicableDBSALT000884
Categories
UNII22QOO9B8KI
CAS number143322-58-1
WeightAverage: 382.519
Monoisotopic: 382.171498776
Chemical FormulaC22H26N2O2S
InChI KeyInChIKey=PWVXXGRKLHYWKM-LJQANCHMSA-N
InChI
InChI=1S/C22H26N2O2S/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3/t19-/m1/s1
IUPAC Name
5-[2-(benzenesulfonyl)ethyl]-3-{[(2R)-1-methylpyrrolidin-2-yl]methyl}-1H-indole
SMILES
CN1CCC[C@@H]1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indoles. These are compounds containing an indole moiety, which consists of pyrrole ring fused to benzene to form 2,3-benzopyrrole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassIndoles
Direct ParentIndoles
Alternative Parents
Substituents
  • Indole
  • Aralkylamine
  • Benzenoid
  • N-alkylpyrrolidine
  • Substituted pyrrole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Sulfonyl
  • Sulfone
  • Pyrrolidine
  • Pyrrole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the acute treatment of migraine with or without aura in adults.
PharmacodynamicsEletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.
Mechanism of actionEletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
Related Articles
AbsorptionWell absorbed after oral administration with a mean absolute bioavailability of approximately 50%.
Volume of distribution
  • 138 L
Protein bindingPlasma protein binding is moderate and approximately 85%.
Metabolism

In vitro studies indicate that eletriptan is primarily metabolized by cytochrome P-450 enzyme CYP3A4. The N-demethylated metabolite of eletriptan is the only known active metabolite.

SubstrateEnzymesProduct
Eletriptan
N-DesmethyleletriptanDetails
Eletriptan
Eletriptan N-oxideDetails
Route of eliminationNot Available
Half lifeThe terminal elimination half-life of eletriptan is approximately 4 hours.
Clearance
  • Renal cl=3.9 L/h
ToxicityBased on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3
Gene symbol: GNB3
UniProt: P16520
rs5443 Not AvailableT AlleleBetter response to drug treatment17361120
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9774
Caco-2 permeable-0.628
P-glycoprotein substrateSubstrate0.6308
P-glycoprotein inhibitor INon-inhibitor0.8046
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterInhibitor0.7
CYP450 2C9 substrateNon-substrate0.6591
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.643
CYP450 1A2 substrateNon-inhibitor0.7021
CYP450 2C9 inhibitorNon-inhibitor0.8103
CYP450 2D6 inhibitorNon-inhibitor0.7615
CYP450 2C19 inhibitorNon-inhibitor0.7519
CYP450 3A4 inhibitorNon-inhibitor0.6355
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6986
Ames testNon AMES toxic0.5945
CarcinogenicityNon-carcinogens0.8556
BiodegradationNot ready biodegradable0.9883
Rat acute toxicity2.5492 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6436
hERG inhibition (predictor II)Inhibitor0.7581
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer ireland pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Tabletoral20 mg
Tabletoral40 mg
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral40 mg/1
Prices
Unit descriptionCostUnit
Relpax 6 20 mg tablet Box156.05USD box
Relpax 6 40 mg tablet Box156.05USD box
Relpax 20 mg tablet25.01USD tablet
Relpax 40 mg tablet25.01USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2198599 No2000-06-062015-05-17Canada
CA2352392 No2006-01-242019-11-01Canada
US5545644 No1996-12-262016-12-26Us
US6110940 No1997-08-292017-08-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityReadily soluble as hydrobromide formulationNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00118 mg/mLALOGPS
logP3.84ALOGPS
logP3.77ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)17.11ChemAxon
pKa (Strongest Basic)8.37ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.17 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.94 m3·mol-1ChemAxon
Polarizability42.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ronald Ogilvie, “Process for the preparation of eletriptan.” U.S. Patent US20050059828, issued March 17, 2005.

US20050059828
General ReferencesNot Available
External Links
ATC CodesN02CC06
AHFS Codes
  • 28:32.28
PDB EntriesNot Available
FDA labelDownload (148 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe metabolism of Eletriptan can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Eletriptan can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aceprometazine.
AcetaminophenThe serum concentration of Eletriptan can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Acetophenazine.
AfatinibThe serum concentration of Eletriptan can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Eletriptan can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Eletriptan can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Eletriptan can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Eletriptan can be increased when it is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Almotriptan.
AmantadineThe serum concentration of Eletriptan can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Eletriptan can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Eletriptan can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amisulpride.
AmitriptylineThe serum concentration of Eletriptan can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amitriptyline.
AmlodipineThe serum concentration of Eletriptan can be increased when it is combined with Amlodipine.
AmoxapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amperozide.
AmprenavirThe serum concentration of Eletriptan can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Eletriptan can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Eletriptan can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Aripiprazole.
ArmodafinilThe metabolism of Eletriptan can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Eletriptan can be decreased when combined with Artemether.
AsenapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Asenapine.
AstemizoleThe serum concentration of Eletriptan can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Eletriptan can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Eletriptan can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Eletriptan can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Eletriptan can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Azaperone.
AzelastineThe serum concentration of Eletriptan can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Eletriptan can be increased when it is combined with Azithromycin.
BenmoxinThe metabolism of Eletriptan can be decreased when combined with Benmoxin.
BenzocaineThe serum concentration of Eletriptan can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Eletriptan can be increased when it is combined with Bepridil.
BetaxololThe metabolism of Eletriptan can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Eletriptan can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bifeprunox.
BiperidenThe serum concentration of Eletriptan can be increased when it is combined with Biperiden.
BoceprevirThe serum concentration of Eletriptan can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Eletriptan can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Eletriptan can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Eletriptan can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Brexpiprazole.
BromocriptineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Bromocriptine.
BromocriptineBromocriptine may increase the vasoconstricting activities of Eletriptan.
BuprenorphineThe serum concentration of Eletriptan can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Eletriptan can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Eletriptan can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Eletriptan is combined with Buspirone.
CabazitaxelThe serum concentration of Eletriptan can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cabergoline.
CabergolineCabergoline may increase the vasoconstricting activities of Eletriptan.
CaffeineThe serum concentration of Eletriptan can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Eletriptan can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Eletriptan can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Eletriptan can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Eletriptan can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Eletriptan can be decreased when it is combined with Carbamazepine.
CariprazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cariprazine.
CaroxazoneThe metabolism of Eletriptan can be decreased when combined with Caroxazone.
CarvedilolThe serum concentration of Eletriptan can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Eletriptan can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Eletriptan can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Eletriptan can be increased when it is combined with Ceritinib.
ChloramphenicolThe metabolism of Eletriptan can be decreased when combined with Chloramphenicol.
ChloroquineThe serum concentration of Eletriptan can be increased when it is combined with Chloroquine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Chlorpromazine.
ChlorpromazineThe serum concentration of Eletriptan can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Eletriptan can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Chlorprothixene.
ChlorprothixeneThe serum concentration of Eletriptan can be increased when it is combined with Chlorprothixene.
CholecalciferolThe metabolism of Eletriptan can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Eletriptan can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Eletriptan can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Eletriptan can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Eletriptan can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Eletriptan can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Eletriptan can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Eletriptan can be increased when it is combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Eletriptan is combined with Citalopram.
ClarithromycinThe serum concentration of Eletriptan can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Eletriptan can be decreased when combined with Clemastine.
ClobazamThe metabolism of Eletriptan can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Eletriptan can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Eletriptan can be increased when it is combined with Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clomipramine.
ClotrimazoleThe metabolism of Eletriptan can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Clozapine.
ClozapineThe metabolism of Eletriptan can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Eletriptan can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Eletriptan can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Eletriptan can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Eletriptan can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Eletriptan can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Eletriptan can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyamemazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Eletriptan can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Eletriptan can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Eletriptan can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Eletriptan can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Eletriptan can be increased when it is combined with Dactinomycin.
DapiprazoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Eletriptan.
DarifenacinThe metabolism of Eletriptan can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Eletriptan can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Eletriptan can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Eletriptan can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Eletriptan can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Eletriptan can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Eletriptan can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desipramine.
DesloratadineThe serum concentration of Eletriptan can be increased when it is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Eletriptan can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Eletriptan can be increased when it is combined with Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dextromethorphan.
DiclofenacThe serum concentration of Eletriptan can be increased when it is combined with Diclofenac.
DigoxinThe serum concentration of Eletriptan can be decreased when it is combined with Digoxin.
DihydroergotamineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Dihydroergotamine.
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Eletriptan.
DiltiazemThe metabolism of Eletriptan can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Eletriptan can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Eletriptan can be increased when it is combined with Dipyridamole.
DolasetronDolasetron may increase the serotonergic activities of Eletriptan.
DoxazosinThe serum concentration of Eletriptan can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Eletriptan can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Eletriptan is combined with Doxepin.
DoxorubicinThe serum concentration of Eletriptan can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Eletriptan can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Eletriptan can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Eletriptan can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Droperidol.
DroxidopaEletriptan may increase the hypertensive activities of Droxidopa.
DuloxetineThe metabolism of Eletriptan can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Duloxetine.
EfavirenzThe serum concentration of Eletriptan can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Eletriptan can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Eletriptan can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Eletriptan can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Eletriptan can be increased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergoloid mesylate.
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Eletriptan.
ErgonovineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergonovine.
ErgonovineErgonovine may increase the vasoconstricting activities of Eletriptan.
ErgotamineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergotamine.
ErgotamineErgotamine may increase the vasoconstricting activities of Eletriptan.
ErythromycinThe metabolism of Eletriptan can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Eletriptan can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Eletriptan can be decreased when combined with Esomeprazole.
EstramustineThe serum concentration of Eletriptan can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Eletriptan can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Eletriptan can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Eletriptan can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Eletriptan can be decreased when it is combined with Etravirine.
FelodipineThe serum concentration of Eletriptan can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fencamfamine.
FentanylThe serum concentration of Eletriptan can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fentanyl.
FexofenadineThe serum concentration of Eletriptan can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Eletriptan can be increased when it is combined with Fidaxomicin.
FloxuridineThe metabolism of Eletriptan can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Eletriptan can be decreased when combined with Fluconazole.
FluorouracilThe metabolism of Eletriptan can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Eletriptan can be increased when it is combined with Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Flupentixol.
FlupentixolThe serum concentration of Eletriptan can be increased when it is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluphenazine.
FluphenazineThe serum concentration of Eletriptan can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Eletriptan can be increased when it is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluspirilene.
FluvastatinThe metabolism of Eletriptan can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Eletriptan can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Fluvoxamine.
FosamprenavirThe metabolism of Eletriptan can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Eletriptan can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Eletriptan can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Frovatriptan.
FurazolidoneThe metabolism of Eletriptan can be decreased when combined with Furazolidone.
Fusidic AcidThe serum concentration of Eletriptan can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Eletriptan can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Eletriptan can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Eletriptan can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Eletriptan can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Eletriptan can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Eletriptan can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the serotonergic activities of Eletriptan.
GrepafloxacinThe serum concentration of Eletriptan can be increased when it is combined with Grepafloxacin.
HaloperidolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Haloperidol.
HaloperidolThe serum concentration of Eletriptan can be increased when it is combined with Haloperidol.
HydracarbazineThe metabolism of Eletriptan can be decreased when combined with Hydracarbazine.
HydrocortisoneThe serum concentration of Eletriptan can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Eletriptan can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Iloperidone.
ImatinibThe metabolism of Eletriptan can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Eletriptan can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Imipramine.
IndinavirThe serum concentration of Eletriptan can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Eletriptan can be increased when it is combined with Indomethacin.
IproclozideThe metabolism of Eletriptan can be decreased when combined with Iproclozide.
IproniazidThe metabolism of Eletriptan can be decreased when combined with Iproniazid.
IrbesartanThe metabolism of Eletriptan can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Eletriptan can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Eletriptan is combined with Isocarboxazid.
IsocarboxazidThe metabolism of Eletriptan can be decreased when combined with Isocarboxazid.
IsoniazidThe metabolism of Eletriptan can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Eletriptan can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Eletriptan can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Eletriptan can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Eletriptan can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Eletriptan can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Eletriptan can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Eletriptan can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Eletriptan can be increased when it is combined with Lapatinib.
LeflunomideThe metabolism of Eletriptan can be decreased when combined with Leflunomide.
LevofloxacinThe serum concentration of Eletriptan can be increased when it is combined with Levofloxacin.
LevomilnacipranThe risk or severity of adverse effects can be increased when Eletriptan is combined with Levomilnacipran.
LevothyroxineThe serum concentration of Eletriptan can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Eletriptan can be increased when it is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Eletriptan is combined with Linezolid.
LiothyronineThe serum concentration of Eletriptan can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Eletriptan can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Eletriptan can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lithium.
LomitapideThe serum concentration of Eletriptan can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Eletriptan can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Eletriptan can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Eletriptan can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Eletriptan can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lorcaserin.
LosartanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.
LovastatinThe metabolism of Eletriptan can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Loxapine.
LuliconazoleThe serum concentration of Eletriptan can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Eletriptan can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Eletriptan can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.
MaprotilineThe serum concentration of Eletriptan can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.
MebanazineThe metabolism of Eletriptan can be decreased when combined with Mebanazine.
MebendazoleThe serum concentration of Eletriptan can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Eletriptan can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Eletriptan can be increased when it is combined with Megestrol acetate.
MelperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Melperone.
MeprobamateThe serum concentration of Eletriptan can be increased when it is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mesoridazine.
MethadoneThe serum concentration of Eletriptan can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methadone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Eletriptan can be decreased when combined with Methotrimeprazine.
Methylene blueThe metabolism of Eletriptan can be decreased when combined with Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Metoclopramide.
MetoprololThe serum concentration of Eletriptan can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Eletriptan can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Eletriptan can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Eletriptan can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Eletriptan can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Eletriptan is combined with Milnacipran.
MinaprineThe metabolism of Eletriptan can be decreased when combined with Minaprine.
MirabegronThe metabolism of Eletriptan can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mirtazapine.
MitomycinThe serum concentration of Eletriptan can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Eletriptan can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Eletriptan can be decreased when it is combined with Mitoxantrone.
MoclobemideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Moclobemide.
MoclobemideThe metabolism of Eletriptan can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Eletriptan can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Molindone.
MorphineThe serum concentration of Eletriptan can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Eletriptan can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Eletriptan can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Naratriptan.
NaringeninThe serum concentration of Eletriptan can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Eletriptan can be increased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nefazodone.
NelfinavirThe serum concentration of Eletriptan can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Eletriptan can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Eletriptan can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Eletriptan can be decreased when combined with Nevirapine.
NialamideThe metabolism of Eletriptan can be decreased when combined with Nialamide.
NicardipineThe serum concentration of Eletriptan can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Eletriptan can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Eletriptan can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Eletriptan.
NisoldipineThe serum concentration of Eletriptan can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Eletriptan can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Eletriptan can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Eletriptan can be decreased when it is combined with Norethisterone.
NortriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nortriptyline.
OctamoxinThe metabolism of Eletriptan can be decreased when combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Olanzapine.
OlaparibThe metabolism of Eletriptan can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Eletriptan can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Eletriptan.
OsanetantThe risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant.
OsimertinibThe serum concentration of Eletriptan can be increased when it is combined with Osimertinib.
P-NitrophenolThe serum concentration of Eletriptan can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Eletriptan can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Eletriptan can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paliperidone.
Palmitic AcidThe serum concentration of Eletriptan can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Eletriptan.
PanobinostatThe metabolism of Eletriptan can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Eletriptan can be increased when it is combined with Pantoprazole.
PargylineThe metabolism of Eletriptan can be decreased when combined with Pargyline.
ParoxetineThe serum concentration of Eletriptan can be increased when it is combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Eletriptan can be increased when combined with Pentobarbital.
PerindoprilThe serum concentration of Eletriptan can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Phenelzine.
PhenelzineThe metabolism of Eletriptan can be decreased when combined with Phenelzine.
PheniprazineThe metabolism of Eletriptan can be decreased when combined with Pheniprazine.
PhenobarbitalThe serum concentration of Eletriptan can be decreased when it is combined with Phenobarbital.
PhenoxypropazineThe metabolism of Eletriptan can be decreased when combined with Phenoxypropazine.
PhenytoinThe metabolism of Eletriptan can be increased when combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pimozide.
PimozideThe serum concentration of Eletriptan can be increased when it is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipotiazine.
PirlindoleThe metabolism of Eletriptan can be decreased when combined with Pirlindole.
PivhydrazineThe metabolism of Eletriptan can be decreased when combined with Pivhydrazine.
Platelet Activating FactorThe serum concentration of Eletriptan can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Eletriptan can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Eletriptan can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Eletriptan can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Eletriptan can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Eletriptan can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Eletriptan can be increased when combined with Primidone.
ProbenecidThe serum concentration of Eletriptan can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Eletriptan can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promazine.
PromazineThe metabolism of Eletriptan can be decreased when combined with Promazine.
PromethazineThe serum concentration of Eletriptan can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promethazine.
PropafenoneThe serum concentration of Eletriptan can be increased when it is combined with Propafenone.
PropericiazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Propericiazine.
PropranololThe serum concentration of Eletriptan can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Eletriptan can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.
PyrimethamineThe metabolism of Eletriptan can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Eletriptan can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.
QuinacrineThe serum concentration of Eletriptan can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Eletriptan can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Eletriptan can be increased when it is combined with Quinine.
RanitidineThe serum concentration of Eletriptan can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Eletriptan can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Rasagiline.
RasagilineThe metabolism of Eletriptan can be decreased when combined with Rasagiline.
ReboxetineThe serum concentration of Eletriptan can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Eletriptan can be increased when it is combined with Regorafenib.
RemoxiprideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Reserpine.
ReserpineThe serum concentration of Eletriptan can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Eletriptan can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Eletriptan can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Eletriptan can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Eletriptan can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.
RitonavirThe serum concentration of Eletriptan can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Rizatriptan.
RolapitantThe serum concentration of Eletriptan can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Eletriptan can be decreased when combined with Ropinirole.
SafrazineThe metabolism of Eletriptan can be decreased when combined with Safrazine.
SaquinavirThe serum concentration of Eletriptan can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Eletriptan.
ScopolamineThe serum concentration of Eletriptan can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Eletriptan can be increased when combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Selegiline.
SelegilineThe metabolism of Eletriptan can be decreased when combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertindole.
SertralineThe serum concentration of Eletriptan can be increased when it is combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertraline.
SildenafilThe metabolism of Eletriptan can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Eletriptan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Eletriptan can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Eletriptan can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Eletriptan can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Eletriptan can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Eletriptan can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Eletriptan can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Eletriptan can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Eletriptan can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Eletriptan can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Eletriptan can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Eletriptan can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Eletriptan can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Eletriptan can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sulpiride.
SumatriptanThe serum concentration of Eletriptan can be increased when it is combined with Sumatriptan.
SumatriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sumatriptan.
SunitinibThe serum concentration of Eletriptan can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Eletriptan can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Eletriptan can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Eletriptan can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Eletriptan can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Eletriptan.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Eletriptan can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Eletriptan can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Eletriptan can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Eletriptan can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Eletriptan can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Eletriptan can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Eletriptan can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Eletriptan can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Eletriptan can be increased when it is combined with Testosterone.
ThioproperazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioproperazine.
ThioridazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioridazine.
ThioridazineThe metabolism of Eletriptan can be decreased when combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.
TicagrelorThe serum concentration of Eletriptan can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Eletriptan can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Eletriptan can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Eletriptan can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Eletriptan can be decreased when combined with Tolbutamide.
ToloxatoneThe metabolism of Eletriptan can be decreased when combined with Toloxatone.
TolvaptanThe serum concentration of Eletriptan can be increased when it is combined with Tolvaptan.
TopiramateThe metabolism of Eletriptan can be decreased when combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Eletriptan.
Trans-2-PhenylcyclopropylamineThe metabolism of Eletriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tranylcypromine.
TranylcypromineThe metabolism of Eletriptan can be decreased when combined with Tranylcypromine.
TrazodoneThe serum concentration of Eletriptan can be decreased when it is combined with Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trazodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trifluoperazine.
TrifluoperazineThe serum concentration of Eletriptan can be increased when it is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Triflupromazine.
TriflupromazineThe serum concentration of Eletriptan can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Eletriptan can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Eletriptan can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trimipramine.
TroleandomycinThe serum concentration of Eletriptan can be increased when it is combined with Troleandomycin.
Valproic AcidThe metabolism of Eletriptan can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Eletriptan can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Eletriptan can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Venlafaxine.
VerapamilThe metabolism of Eletriptan can be decreased when combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vilazodone.
VinblastineThe serum concentration of Eletriptan can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Eletriptan can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Eletriptan can be increased when it is combined with Vinorelbine.
VoriconazoleThe serum concentration of Eletriptan can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vortioxetine.
ZafirlukastThe metabolism of Eletriptan can be decreased when combined with Zafirlukast.
ZimelidineThe serum concentration of Eletriptan can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ziprasidone.
ZiprasidoneThe metabolism of Eletriptan can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zolmitriptan.
ZotepineThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.
Food Interactions
  • Exposure to the product (area below curve) and maximum concentrations are increased when product is taken with a high-fat meal.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  3. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjo M: Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol. 2005 May;45(5):476-84. [PubMed:15821444 ]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
  5. Strijbos PJ, Parsons AA, Fugelli A: Eletriptan Pfizer. Curr Opin Investig Drugs. 2002 Sep;3(9):1359-68. [PubMed:12498013 ]
  6. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR: Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000 Oct 27;407(1-2):165-73. [PubMed:11050304 ]
  3. Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L: Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci. 2000 Nov;12(11):3991-4002. [PubMed:11069595 ]
  4. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
  5. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS: Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res. 2002 Oct 25;953(1-2):181-8. [PubMed:12384251 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1F
Uniprot ID:
P30939
Molecular Weight:
41708.505 Da
References
  1. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R: Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. [PubMed:10193663 ]
  2. Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR: Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. [PubMed:11834243 ]
  3. Jahnichen S, Radtke OA, Pertz HH: Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):54-63. Epub 2004 Jun 8. [PubMed:15185063 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. [PubMed:11513839 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. [PubMed:12814962 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:25